Lactobacillus gasseri: The Probiotic Strain for Weight and Women's Health

← Back to articles

Most probiotic trials use generic multi-strain products and produce correspondingly generic outcomes. A handful of specific strains, however, have well-characterized clinical effects tied to documented mechanisms. Lactobacillus gasseri — particularly strains SBT2055 and BNR17 — is one of the better-documented examples, with controlled trials in adiposity reduction and gynecological health.

The Snow Brand Weight Trial

The headline study is Kadooka 2010 (European Journal of Clinical Nutrition; PMID 20216555). Eighty-seven adults with obese tendencies (BMI 24.2–30.7) were randomized to a fermented milk containing L. gasseri SBT2055 (about 2×10¹⁰ CFU/day, from FM at 10⁸ CFU/g × 200 g/day) or matched placebo fermented milk for 12 weeks. The active group showed a 4.6% reduction in abdominal visceral fat area, plus significant reductions in body weight (1.4%), BMI (1.5%), waist (1.8%), and hip (1.5%). A 2013 follow-up RCT in the British Journal of Nutrition (Kadooka et al.; PMID 23614897) tested lower CFU doses (10⁶ and 10⁷ CFU/g) in 210 healthy Japanese adults with large visceral fat areas and reported similar — in fact slightly larger — visceral fat reductions (about 8% in both lower-dose groups), confirming dose responsiveness rather than ceiling. In both trials, effects attenuated after stopping the product, suggesting ongoing microbiota modulation rather than permanent change.

Mechanism: Postbiotic Lipid Modulation

L. gasseri produces conjugated linoleic acid (CLA) and expresses bile salt hydrolase, which together alter lipid absorption and fecal fat excretion. It also reduces intestinal inflammation markers (serum LPS, TNF-α) that contribute to metabolic dysfunction in obesity. The effect size is modest — comparable to a well-executed diet intervention sustained for 8 weeks — but the safety and cost profile are favorable.

Bacterial Vaginosis and Urogenital Health

L. gasseri is one of the dominant species in healthy vaginal microbiota, and strain-specific oral or vaginal formulations (often combined with L. rhamnosus) have shown benefit in recurrent bacterial vaginosis (BV) and urinary tract infections. Systematic reviews of probiotics for urogenital infections in women have reported about a 50% reduction in BV recurrence at 3–6 months when L. gasseri- or L. rhamnosus-containing products are used adjunctively or after standard antibiotic therapy.

Strain Specificity Matters

Not all L. gasseri strains reproduce the weight or urogenital effects seen in these trials. The studied strains include SBT2055 (weight), BNR17 (visceral fat / insulin sensitivity), and LA-14 / LN-101 (urogenital). Buying a generic "L. gasseri probiotic" without strain identification may miss the effect entirely. Reputable products name the specific strain on the label.